Please email us at [email protected] with our item No, NDC#, UPC# or the product link if you have any quetions. We are located in Oceanside, California. Search over 110,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name. Please note, Prescription items can only be ordered by a Drug Manufacturer, Wholesaler, Hospital, Governmental Medical Facility, VA, Pharmacy, Physician, Physician Assistant, Nurse Practitioner, Dentist, Podiatrist, Optometrist, Veterinarian, Naturopath, Licensed Lab, Physical Therapist & Pharmacist in their scope of practice. No order will ship, unless you you have provided us the Medical License (and DEA Lic. in case of controlled drug) and we had verified that. Rx items can only be shipped to AZ, AR, CA, CT, DE, FL, GA, GU, HI, IL, KS, KY, LA, ME, MA, MI, NJ, NY, PA, PR, TX, TN, VA, WA, WI and WV. If you are an International Physician or Pharmacist, please contact us before ordering.


Menu

Rx Item-Sirturo ( Bedaquiline Fumarate ) 100Mg 188 Tab By Janssen Pharma

NDC No. 59676-701-01 59676-0701-01 UPC/GTIN No. 3-59676-70101-9 MPN 70101 Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,PhImage 1 of Rx Item-Sirturo ( Bedaquiline Fumarate ) 100Mg 188 Tab By Janssen PharmaImage 2 of Rx Item-Sirturo ( Bedaquiline Fumarate ) 100Mg 188 Tab By Janssen PharmaImage 3 of Rx Item-Sirturo ( Bedaquiline Fumarate ) 100Mg 188 Tab By Janssen PharmaImage 4 of Rx Item-Sirturo ( Bedaquiline Fumarate ) 100Mg 188 Tab By Janssen PharmaImage 5 of Rx Item-Sirturo ( Bedaquiline Fumarate ) 100Mg 188 Tab By Janssen PharmaImage 6 of Rx Item-Sirturo ( Bedaquiline Fumarate ) 100Mg 188 Tab By Janssen PharmaImage 7 of Rx Item-Sirturo ( Bedaquiline Fumarate ) 100Mg 188 Tab By Janssen PharmaVisit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comImage 10 of Rx Item-Sirturo ( Bedaquiline Fumarate ) 100Mg 188 Tab By Janssen Pharma

Rx Item-Sirturo ( Bedaquiline Fumarate ) 100Mg 188 Tab By Janssen Pharma

$0.00

Item No.: RX59676-701-01 NDC No.59676070101 UPC No.:359676701019 NDC No. 59676-701-01 59676-0701-01 UPC/GTIN No. 3-59676-70101-9 MPN 70101 Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,ResearchCo.,Uni.,VA,Vet & Wholesalers in scope of practice can order this RX item. Rx Item No. Rx59676-701-01 Sirturo 100mg 188 tab by Janssen Pharma Item No. 59676-0701-01 NDC No. 59676-701-01 59676070101 5

Have a question?

  Out of stock, please email us with the item number or product link at [email protected] for the quantity available, current pricing and eligibility to purchase.

SIRTURO- bedaquiline fumarate tablet
Janssen Products, LP

WARNINGS: INCREASED MORTALITY; QT PROLONGATION

Increased Mortality

An increased risk of death was seen in the SIRTURO treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81, 2.5%) in one placebo-controlled trial. Only use SIRTURO when an effective treatment regimen cannot otherwise be provided [see Indications and Usage (1) and Warnings and Precautions (5.1)].


QT Prolongation

QT prolongation can occur with SIRTURO. Use with drugs that prolong the QT interval may cause additive QT prolongation. Monitor ECGs. Discontinue SIRTURO if significant ventricular arrhythmia or if QTcF interval prolongation of greater than 500 ms develops [see Warnings and Precautions (5.2)].
1 INDICATIONS AND USAGE

SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adults (18 years and older) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided. Administer SIRTURO by directly observed therapy (DOT).

This indication is approved under accelerated approval based on time to sputum culture conversion [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Limitations of Use:

Do not use SIRTURO for the treatment of:
Latent infection due to Mycobacterium tuberculosis
Drug-sensitive tuberculosis
Extra-pulmonary tuberculosis
Infections caused by non-tuberculous mycobacteria
The safety and efficacy of SIRTURO in the treatment of HIV infected patients with MDR-TB have not been established as clinical data are limited [see Clinical Studies (14)].
2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Instructions
Administer SIRTURO by directly observed therapy (DOT).
Use SIRTURO only in combination with other anti-mycobacterial drugs [see Dosage and Administration (2.3)].
Emphasize the need for compliance with full course of therapy.
2.2 Required Testing Prior to Administration
Prior to treatment with SIRTURO, obtain the following:

Susceptibility information for the background regimen against M. tuberculosis isolate if possible [see Dosage and Administration (2.3)]
ECG [see Warnings and Precautions (5.2)]
Serum potassium, calcium, and magnesium concentrations [see Warnings and Precautions (5.2)]
Liver enzymes [see Warnings and Precautions (5.3)]
2.3 Recommended Dosage in Combination Therapy
Only use SIRTURO in combination with at least 3 other drugs to which the patient's MDR-TB isolate has been shown to be susceptible in vitro. If in vitro testing results are unavailable, SIRTURO treatment may be initiated in combination with at least 4 other drugs to which the patient's MDR-TB isolate is likely to be susceptible. Refer to the prescribing information of the drugs used in combination with SIRTURO.

The recommended dosage of SIRTURO is 400 mg orally once daily for the first two weeks, followed by 200 mg orally three times per week (with at least 48 hours between doses) for 22 weeks (total duration of 24 weeks).

The SIRTURO tablet should be swallowed whole with water and taken with food.

If a dose is missed during the first 2 weeks of treatment, do not administer the missed dose (skip the dose and then continue the daily dosing regimen). From Week 3 onwards, if a 200 mg dose is missed, administer the missed dose as soon as possible, and then resume the 3 times a week dosing regimen.

3 DOSAGE FORMS AND STRENGTHS

SIRTURO tablets, 100 mg are uncoated white to almost white round biconvex with debossing of "T" over "207″ on one side and "100″ on the other side.

NDC No. 59676-701-01 59676-0701-01 UPC/GTIN No. 3-59676-70101-9 MPN 70101 Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Ph
RX ITEM-Sirturo ( Bedaquiline Fumarate )
NDC No. 59676-701-01 59676-0701-01 UPC/GTIN No. 3-59676-70101-9 MPN 70101 Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Ph

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:[email protected]